BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
January 26, 2023 14:05 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Global Lung Injury Market
Insights on the Lung Injury Global Market to 2027 - Pipelines Drugs for Treatment of Acute Lung Injury Presents Opportunities
September 07, 2022 05:33 ET | Research and Markets
Dublin, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Lung Injury Market (2022-2027) by Therapy, Injury, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis"...
Survival Benefit Achieved by Combining Rhu-pGSN with Meropenem
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...